Total number of patient | 62 |
---|---|
Sex | |
Male | 33 |
Female | 29 |
Median age | 62 years (range, 37–88) |
<60 years | 16 |
>60 years | 46 |
Disease type | Number of patient |
IgG | 35 |
IgA | 15 |
Smouldering | 4 |
Free light chain disease/Bence Jones myeloma | 8 |
Free light chain | |
κ | 32 |
λ | 26 |
No light chain | 4 |
Clinical stage | |
I | 4 |
II | 20 |
III | 38 |
Higher staging after MRI scan compared to skeletal survey | 14 |
Higher staging after MIBI scan compared to skeletal survey | 15 |
Lines of treatment | |
First-line treatment | |
Thalidomide/dexamethasone | 57/62 |
Radiotherapy only | 2/62 |
Lenalidomide second-line therapy | 12/57 |
Bortezomib second-line therapy | 8/57 |
No treatment | 3/62 |
Bone marrow transplantation salvage therapy | 10/57 |
Cytogenetic risk stratification | |
Normal karyotype | 36 |
Complex cytogenetic with >5 abnormalities | 11 |
Complex cytogenetic including chromosome 13 abnormality | 4 |
Abnormal karyotype with less than 5 cytogenetic abnormalities | 5 |
Insufficient marrow cells or unable to grow bone marrow culture | 6 |
MIBI, Sestamibi Technetium-99m-bone marrow.